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form of regulation of the Hippo signaling
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The Hippo signaling pathway is responsible for
regulating the function of TEAD family transcription
factors inmetazoans. TEADs, with their co-activators
YAP/TAZ, are critical for controlling cell differentia-
tion and organ size through their transcriptional acti-
vation of genes involved in cell growth and prolifera-
tion. Dysregulation of the Hippo pathway has been
implicated inmultiple forms of cancer. Here, we iden-
tify a novel form of regulation of TEAD family pro-
teins. We show that human TEADs are palmitoylated
at a universally conserved cysteine, and report the
crystal structures of the human TEAD2 and TEAD3
YAP-binding domains in their palmitoylated forms.
These structures show a palmitate bound within a
highly conserved hydrophobic cavity at each pro-
tein’s core. Our findings also demonstrate that this
modification is required for proper TEAD folding
and stability, indicating a potential new avenue for
pharmacologically regulating the Hippo pathway
through the modulation of TEAD palmitoylation.
INTRODUCTION
The Hippo signaling pathway is a highly conserved kinase
cascade that controls organ size and tissue homeostasis (Halder
and Johnson, 2011; Zhao et al., 2011). The key downstream ef-
fectors include yes-associated protein (YAP) and its paralog,
transcriptional co-activator with PDZ-binding motif (TAZ). These
proteins interact with transcription factors in the nucleus to
induce gene expression (Cao et al., 2008; Ota and Sasaki,
2008; Zhao et al., 2008). Upon Hippo pathway activation,
Lats1/2 phosphorylates YAP, promoting its sequestration and
inactivation in the cytoplasm by interaction with 14-3-3 proteins.
Conversely, when this pathway is inactivated YAP is not phos-
phorylated and translocates into the nucleus, where it forms aStructure 24, 17complex with TEA domain (TEAD) transcription factors and co-
activates the expression of multiple genes involved in cell fate
determination, polarity, proliferation, and survival (Tian et al.,
2010).
Defects in Hippo pathway regulation have been linked to un-
controlled cell proliferation and tumorigenesis (Harvey et al.,
2013;Moroishi et al., 2015; Santucci et al., 2015).Multiple human
cancers, including breast, liver, and pharyngeal cancers, show
amplification or overexpression of the YAP gene (Liu et al.,
2010; Overholtzer et al., 2006; Steinhardt et al., 2008; Zender
et al., 2006). In addition, induced expression of YAP has been re-
ported to trigger transformation of normal epithelial cells into
metastatic cells (Overholtzer et al., 2006), and recent data have
revealed that YAP is essential for the progression of pancreatic
ductal adenocarcinoma in Kras-mutant mice (Kapoor et al.,
2014). Since inhibition of the Hippo pathway leads to an activa-
tion of downstream genes, kinase components upstream of YAP
phosphorylation are tumor suppressors, while YAP and TEAD,
which together form a transcription co-activation complex, can
promote cellular transformation. Understanding the regulation
and interactions of these two proteins is therefore of critical
importance to our understanding of tumorigenesis.
Crystal structures of the C-terminal YAP-binding domain
(YBD) of TEAD1, TEAD2, and TEAD4 in the apo or co-activator
bound states (Chen et al., 2010; Jiao et al., 2014; Li et al.,
2010; Pobbati et al., 2012; Tian et al., 2010; Zhou et al., 2014)
show that this domain adopts an immunoglobulin G-like fold,
with two b sheets packing against each other to form a b sand-
wich capped with a pair of a helices (Figure 1A). The co-activator
bound complex structures with YAP or vestigial-like proteins
(Vgll) reveal that these proteins interact with TEAD via three
distinct binding interfaces, with the majority of YAP-binding
energy being driven by a short stretch of amino acids (YAP 86–
100) that form a twisted-coil conformation, and bind onto a
deep pocket centered around residue K289 in TEAD1.
Many proteins have been found to be regulated through S-pal-
mitoylation, a highly conserved process occurring in all eukary-
otic organisms that involves the attachment of 16-carbon fatty
acids onto cysteine residues via a reversible thioester linkage
(Chamberlain and Shipston, 2015; Hannoush, 2015). Palmitate9–186, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 179
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Figure 1. Structure of TEAD2 and TEAD3 Show S-Palmitoylation at a Conserved Cysteine
(A) Structural alignment of the YBDs of the four human TEAD paralogs. TEAD1-YBD (PDB: 4RE1) is shown in green. TEAD2-YBD is shown in salmon. TEAD3-YBD
is shown in blue. TEAD4-YBD (PDB: 4EAZ) is shown in yellow.
(B) Crystal structure of the TEAD3-YBD with unassigned Fo – Fc electron density (green mesh) contoured to 3.0s.
(C) Crystal structure of the TEAD2-YBD with unassigned Fo – Fc electron density (green mesh) contoured to 3.0s.
(D) MS/MS spectra of the TEAD2 palmitoylated tryptic peptide (top) and a synthetic standard (bottom).
(E) Close-up view of palmitate bound within the hydrophobic TEAD3 (top) and TEAD2 (bottom) lipid-binding pockets. 2Fo – Fc electron density (gray mesh) is
contoured to 1.0s. Protein is shown as a surface representation with hydrophobic residues colored in orange.
See also Figure S1.can either be added to proteins spontaneously or enzymatically
by a family of DHHC motif-containing palmitoyltransferases, of
which there are 23 in humans (Fukata and Fukata, 2010; Linder
and Deschenes, 2007). Although there is no known consensus
sequence for palmitoylation, palmitoylated cysteines share com-
mon characteristics including neighboring amino acids that are
basic, a proximity to other lipidation sites, and an adjacent hy-
drophobic patch or core to stabilize the lipid modification (Ai-
cart-Ramos et al., 2011; Salaun et al., 2010). Several functional
consequences of protein palmitoylation have been identified,
such as altered signaling or enzymatic activity, modified traf-180 Structure 24, 179–186, January 5, 2016 ª2016 Elsevier Ltd All rigficking, increased affinity for cellular membranes, and differential
stability (Linder and Deschenes, 2007).
Here we use a combination of structural, biophysical, and cell
biological techniques to show that all four human TEAD homo-
logs are S-palmitoylated in mammalian cells. Mutation of the
acylated cysteine to alanine results in a complete loss of TEAD
in cells, and depalmitoylation of TEAD is destabilizing, high-
lighting the critical nature of this adduct. Immunofluorescence
microscopy in multiple mammalian cell types reveals that
TEAD does not stably associate with the nuclear envelope, sug-
gesting that the function of this modification may solely behts reserved
Table 1. Crystallographic Data Collection and Refinement
Statistics
TEAD2 (PDB: 5EMV) TEAD3 (PDB: 5EMW)
Data Collection
Wavelength (A˚) 0.9787 0.9795
Space group I121 P212121
Cell dimensions
a, b, c (A˚) 79.83, 61.25, 112.67 65.31, 123.53, 150.73
a, b, g () 90, 101.89, 90 90, 90, 90
Resolution (A˚) 58.32–2.00 (2.05–2.00) 95.54–2.55 (2.66–2.55)
Rmerge 0.063 (0.549) 0.109 (0.631)
Mean I/sI 9.9 (2.0) 9.5 (2.5)
Completeness (%) 100 (100) 94.9 (96.8)
Redundancy 3.8 (3.8) 5.0 (4.9)
Refinement
Resolution (A˚) 53.54–2.00 95.54–2.55
No. of reflections 36,163 (2,696) 38,149 (4,695)
Rwork/Rfree 0.2053/0.2295 0.1887/0.2241
No. of atoms
Protein 3236 6597
Ligand/ion 34 70
Water 168 167
B factors (A˚2)
Protein 47.15 42.10
Ligand/ion 57.7 47.48
Water 48.359 43.99
Root-mean-square deviations
Bond lengths (A˚) 0.0153 0.0046
Bond angles () 1.294 0.845
Ramachandran plot
Favored (%) 98.4 98.4
Allowed (%) 1.6 1.6
Outliers (%) 0 0restricted to overall structural stability of TEAD. Together, these
data reveal a novel mode of regulation for TEAD transcription
factors, and ultimately Hippo signaling, suggesting a potential
new approach for pharmacological intervention in diseases
associated with the dysregulation of this pathway.
RESULTS
TEAD Paralogs Are Palmitoylated at a Conserved
Cysteine
The four human TEAD protein YBDs (TEAD-YBDs) share an
average of 73% sequence identity. TEAD2-YBD is the most
divergent among these transcription factors, containing a short
insertion and sharing an average pairwise identity with the
YBDs of other human TEAD paralogs of 67%. Several crystal
structures have been reported characterizing the YBDs of hu-
man TEAD1, TEAD2, and TEAD4 proteins in either the apo state
or in complex with YAP or Vgll proteins (see below). We sought to
structurally characterize TEAD3-YBD and, to this end, crystal-
lized the protein and solved the structure to 2.55 A˚ resolution (Ta-Structure 24, 17ble 1, Figure 1B). As expected, TEAD3-YBD shares the same
overall fold as other TEAD-YBD paralogs. An alignment of the
TEAD3-YBD Ca carbons to TEAD1-YBD (PDB: 4RE1), TEAD2-
YBD (discussed below), and TEAD4-YBD (PDB: 4EAZ) struc-
tures gave root-mean-square deviations of 0.509, 0.445, and
0.535 A˚, respectively (Figure 1A). The overall TEAD3-YBD fold
is composed primarily of two adjacent b sheets that are splayed
at one end to create a hydrophobic cavity capped by two a he-
lices. At the entrance to this cavity lies a universally conserved
cysteine residue (C371). To our surprise, we found significant
Fo – Fc electron density resembling that of an aliphatic chain in
this hydrophobic pocket that was connected directly to C371
(Figure 1B). Interestingly, upon solving the structure of the
TEAD2-YBD to 2.00 A˚ resolution, a similar Fo – Fc electron den-
sity was present and connected to C380 (Table 1, Figure 1C).
Given the shape of the density, its location in a hydrophobic
pocket, and its proximity to a conserved surface cysteine, we
surmised that TEAD3 and TEAD2 are likely lipidated. Since these
proteins were obtained by expression in Escherichia coli, which
lacks palmitoyltransferases, we hypothesize that these pro-
teins undergo a spontaneous, non-catalytic lipidation when ex-
pressed in bacterial cells.
To confirm the identity of the additional electron density in
our structures, we used intact and tandem mass spectrometry
(MS/MS) analysis of the bacterially expressed TEAD2-YBD.
The deconvoluted mass spectrum of intact TEAD2-YBD shows
two predominant masses of 30,402.20 Da and 30,640.31 Da
(Figure S1A). The 238-Da difference is consistent with a palmi-
tate modification. The presence of a non-palmitoylated mass is
likely due to reducing reagent in our purification; however, we
believe that palmitate is likely still non-covalently present in the
TEAD2-YBD hydrophobic pocket in this species based on
experiments described below. Peptide mapping experiments
were performed to identify the site of palmitoylation in TEAD2-
YBD, and three cysteine-containing tryptic peptides were
identified using a C18 column (DTQELLLCTAYVFEVSTSER;
VCSFGK; SPMCEYLVNFLHK). Selected ion-monitoring experi-
ments were subsequently performed using direct infusion of
the TEAD2-YBD digest to look for S-palmitolyated versions of
the three detected cysteine-containing peptides. A singly pro-
tonated tryptic peptide atm/z 1818.9721 consistent with the pal-
mitolyated peptide SPMCpEYLVNFLHK (3 ppmmass error) was
observed (Figure S1B). To further reinforce that the 238-Damass
addition is due to a palmitoylation event, we synthesized a palmi-
toyl peptide standard by performing a palmitoylation reaction on
the synthetic peptide SPMCEYLVNFLHK (see Supplemental
Experimental Procedures). The MS/MS spectra of the tryptic
peptide from the TEAD2-YBD digest (Figure 1D, top) and the
synthetic standard (Figure 1D, bottom) are superimposable,
providing unequivocal evidence that TEAD2-YBD is S-palmitoy-
lated at C380.
Based on these findings, we modeled an S-palmitoylated
cysteine into the unexpected electron densities in our crystal
structures at C380 of TEAD2-YBD and C371 of TEAD3-YBD (Fig-
ure 1E). The B factors for these ligands are similar to those of the
proteins as awhole (Table 1), albeit slightly higher, potentially due
to the presence of reducing reagent in our protein purifications
and thermal motion of the palmitate within the lipid-binding
site. The hydrophobic residues forming the TEAD lipid-binding9–186, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 181
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Figure 2. Mammalian Expressed TEADs Are Palmitoylated
(A) Metabolic labeling of TEAD paralogs with Alk-C16 chemical probes in
HEK293T cells. a-FLAG-680 and SA-800 are antibodies directed against the
FLAG tag of TEAD or biotinylated fatty acid, respectively.
(B) Alkyne modified fatty acids of varying length were incubated on HEK293T
cells transfected with each of the four TEAD paralogs. Alk-C# denotes the
number of carbons on each fatty acid.
IP, immunoprecipitation. See also Figure S2.site are highly conserved among all TEAD paralogs, with only
five residues diverging in one of the four family members (Fig-
ure S1C). However, despite this conservation, lipidation of the
YBD of TEAD proteins has not previously been reported. This
finding led us to reexamine the electron density maps for every
publicly available TEAD-YBD crystal structure to look for possible
lipid electron density (Figure S1D). This analysis revealed that a
similar electron density is present to varying degrees in every
TEAD-YBD crystal structure deposited to date. Differing levels
and types of reducing agents used to purify TEAD-YBD proteins,
as well as potentially varying levels of lipid flexibility within the
binding pocket, likely account for differences in palmitate site oc-
cupancy between each study and within our own experiments. In
sum,our structural andMSstudiesof TEADproteinYBDs indicate
that these proteins are palmitoylated at C344 of TEAD1, C380 of
TEAD2, C371 of TEAD3, and C360 of TEAD4.182 Structure 24, 179–186, January 5, 2016 ª2016 Elsevier Ltd All rigTEAD Paralogs Are Palmitoylated in Mammalian Cells
As our structural work used bacterially expressed proteins, we
sought to confirm that the TEAD paralogs are also palmitoylated
in mammalian cells. Using previously established methods (Gao
and Hannoush, 2014; Hannoush, 2012; Hannoush and Arenas-
Ramirez, 2009) we metabolically labeled transiently expressed
C-terminally FLAG-tagged full-length TEAD paralogs or GFP (as
a control) in HEK293T cells with a clickable u-alkynyl palmitate
analog (Alk-C16) (Figure S2A). A FLAG immunoprecipitation
was performed, and the alkyne-labeled palmitoylated proteins
were chemoselectively ligated to biotin by a Cu(1)-catalyzed
alkyne-azide [3 + 2] Huisgen cycloaddition reaction. Anti-FLAG
AlexaFluor 680 antibody and streptavidin-IRDye 800 were used
to monitor TEAD and palmitoylation status, respectively, using
western blot analysis. In corroboration of our structural charac-
terization, we found that all four TEAD paralogs are palmitoylated
inmammalian cells (Figure 2A).Using alkynyl fatty acid analogs of
various chain lengths in a similar assay, we observed that C16
fatty acid chains were the most preferred across all four TEAD
proteins, but that C14 (myristoyl) fatty acids were also incorpo-
rated, with C13 and C18 lipid lengths observed to a much lesser
and variable extent (Figure 2B).
TEAD Palmitoylation Is Not Dynamic and Is Required for
Protein Stability
Recent studies focused on understanding the dynamics of
palmitoylation show that addition and removal of this modifica-
tion is important for the regulation of protein localization, protein
stability, and fine-tuning the activity of proteins, analogous to
phosphorylation or ubiquitination (Salaun et al., 2010). For
example, the Ras cycling pathway uses cycles of palmitoylation
and depalmitoylation to regulate its localization in the cell and,
subsequently, its signaling function (Rocks et al., 2005). To deter-
mine the rate of turnover of TEAD2 palmitoylation in mammalian
cells, we used a pulse-chase approach with Alk-C16. HEK293T
cells transiently transfected with full-length TEAD2-FLAG were
pulse labeled with Alk-C16 overnight and then chased with com-
plete medium lacking Alk-C16 over the course of 48 hr. The
depalmitoylation rate of TEAD was very slow during the time
course, with a 40% reduction of palmitoylation observed after
the 48-hr chase period (Figures 3A and 3B). These data suggest
that TEAD palmitoylation is not dynamic but rather most likely
co-exists with the protein throughout its lifetime until its ultimate
degradation. The irreversible nature of TEAD S-palmitoylation
is rather uncharacteristic for S-palmitoylated proteins due to
the reversible and dynamic nature of the thioester bond, and is
more analogous to that of Wnt proteins, which are O-palmitoy-
lated (Gao and Hannoush, 2014), and Hedgehog proteins, which
are N-palmitoylated (Buglino and Resh, 2012).
To investigate the functional role of TEAD palmitoylation,
we mutated either the palmitoylated cysteine or an adjacent
conserved lysine residue located 6.6 A˚ away from the cysteine
(as measured from the sulfur atom of the cysteine to the lysine
ε-amino group), and analyzed protein steady-state levels (Fig-
ures S3A and S3B). We reasoned that this lysine residue might
lower the pKa of the cysteine and thereby enable spontaneous
palmitoylation. Full-length wild-type, C380A, or K357A TEAD2-
FLAG were transiently transfected into HEK293T cells. Cells
were lysed and separated into soluble and insoluble fractions,hts reserved
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(A) Palmitoylation turnover measurements for full-
length TEAD2 using an overnight Alk-C16 pulse
followed by a chase with unmodified complete
medium over five time points.
(B) Quantification of fraction of palmitoylated
TEAD2 from (A). Each point represents the ratio of
a single experiment with SA-800 band intensity
(palm-TEAD) measured versus a-FLAG-680
(TEAD) band intensity at each time point. Error
bars represent SD of n = 4 experiments with sig-
nificance reported (**p < 0.01 by two-way ANOVA
and Dunnett’s multiple comparison test).
(C) Western blot protein-level analysis of full-
length TEAD2 wild-type, C380A, and K357A
constructs in HEK293T cells. Cells were fraction-
ated into soluble and insoluble fractions and
blotted against FLAG and GAPDH.
(D) Thermal denaturation curves for TEAD2-YBD
(blue) and TEAD2-YBD that has been treated with
hydroxylamine (red). Data represent the averages
of three separate measurements. Error bars
represent SD of n = 3.
See also Figure S3.and subjected to SDS-PAGE and western blot analysis using
antibodies against the FLAG tag or GAPDH as a loading control
(Figure 3C). Interestingly, both the C380A and K357A mutant
TEAD2 proteins displayed a substantial loss of overall protein
levels when compared with the wild-type protein. We believe
the enriched amount of wild-type protein found in the insoluble
fraction may be attributed to overexpressed TEAD2 that is pre-
sent in the nucleus, since the lysis procedure does not break
up the nuclear membrane.
The loss of TEAD2 when either C380 or K357 are mutated to
alanine suggested that palmitoylation is required for protein stabil-
ity. To test this directly we treated TEAD2 with hydroxylamine, a
strong reducing agent known to specifically cleave thioester
bonds at neutral pH. We then measured the thermal stabilities of
the treated and non-treated forms of TEAD2 by differential scan-
ning fluorimetry. Despite the possibility that the palmitate may
still be non-covalently bound in the lipid-binding pocket of the hy-
droxylamine-treated protein, this analysis showed a dramatic
decrease in Tm from 61.1 ± 0.2
C for the palmitoylated protein,
to 48.8 ± 0.8C for the hydroxylamine-treated protein (Figure 3D),
demonstrating that TEAD palmitoylation stabilizes the protein.
TEAD Is Not Stably Associated with the Nuclear
Envelope
Since palmitoylation increases the hydrophobicity of cyto-
plasmic proteins, this post-translational modification has been
shown to promote their association, permanently or temporarily,
with cholesterol- and sphingolipid-rich lipid rafts (Brown, 2006;
Yang et al., 2010). Because TEAD is a transcription factor, we
hypothesized that its palmitoylation may function to localize it
onto the nuclear envelope. We used immunofluorescence and
confocal microscopy to assess the subcellular localization of
native TEAD in four mammalian tumor cell lines: a model cervi-
cal cancer cell line, HeLa; a YAP overexpressing colon cancer
cell line, OUMS-23; and two pancreatic tumor-derived cell lines
with either YAP overexpression or TEAD4 amplification, SW-Structure 24, 171990 and PATU-8902, respectively. All cell lines were grown in
chamber slides for 24 hr before fixing, permeabilizing, and incu-
bating with antibodies against pan-TEAD and a nuclear pore
component protein, NUP98, to serve as a nuclear envelope
marker (see Experimental Procedures). In all four cell lines we
observe a diffuse TEAD staining located exclusively throughout
the nucleoplasm, with little to no staining detected in the cyto-
plasm (Figures 4 and S4). In contrast, NUP98 displays a diffuse
staining pattern throughout the nucleus, with the highest signal
intensity observed in a ring around the nucleus, corresponding
to the nuclear envelope of the cell. When the fluorescence pat-
terns of NUP98 and TEAD are compared with one another no
appreciable co-localization is observed, leading us to conclude
that TEAD is not stably associated with the nuclear envelope
under these equilibrium-based conditions.
DISCUSSION
As the furthest downstream regulators in the Hippo signaling
pathway, TEAD transcription factor stability is of critical impor-
tance to cell growth and proliferation. We have solved the first
structure of the TEAD3-YBD, demonstrating its high level of
structural similarity to the analogous domains of other human
TEAD-YBDs. More importantly, our structural studies of the
TEAD2- and TEAD3-YBDs have identified an S-palmitoylation
site on TEAD proteins. To date, the importance of protein S-pal-
mitoylation has centered on the fact that it is a reversible hy-
drophobic modification, the presence or absence of which can
affect the localization, function, and regulation of proteins
dynamically throughout the cell cycle. Surprisingly, S-palmitoyla-
tion of TEADdoes not seem to alter protein localization and/or as-
sociation to a membrane surface, leading us to conclude that
TEAD either does not interact with the nuclear envelope or any
other membrane-bound organelle or, if it does, the association
rate is too fast to measure under equilibrium conditions. Instead,
our thermal stability data indicate that TEAD palmitoylation is9–186, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 183
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Figure 4. Immunofluorescence of Native
TEAD and NUP98 in Tumor Cell Lines
Cells were fixed and stained for TEAD (magenta),
NUP98 (green), and DNA (DAPI, blue) in HeLa and
OUMS-23 cells. DIC overlay includes DIC and all
fluorescent channels. Insets show indicated re-
gions at higher magnification. All images repre-
sent a single confocal optical section. Yellow
dotted lines represent cell boundaries. Scale bar
represents 20 mm. See also Figure S4.directly responsible for the overall stability of the protein.
There are a handful of studies showing that, at least in part, pal-
mitoylation contributes to overall protein stability. For example,
palmitoylation of the A1 adenosine G-protein-coupled receptor
protects newly synthesized proteins from being proteolytically
cleaved and subsequently degraded, with an apparent 9-fold
reduction in half-life of the non-palmitoylated receptor (Gao
et al., 1999).
Most current drug discovery efforts have focused on trying to
antagonize the TEAD-YAP interaction through their protein-pro-
tein interface (Liu-Chittenden et al., 2012; Santucci et al., 2015;
Zhou et al., 2014). It remains to be seen whether the interplay be-
tween the palmitoylation of TEAD and the various degradation
pathways of cells may prove to be an attractive strategy for ther-
apeutic intervention in the Hippo pathway. Intriguingly, it has
been demonstrated recently that the TEAD central pocket is
targetable with small molecules such as flufenamic acid and its
analogs. These molecules inhibit the transcription of genes nor-
mally upregulated during YAP overexpression without affecting
the TEAD-YAP interaction (Pobbati et al., 2015). Although the
exact mechanism of TEAD inhibition by flufenamic acid has not
been determined, in light of the present findings it seems likely
that these molecules displace the palmitate from the hydropho-
bic core, which may lead to destabilization of TEAD proteins
in vivo.
Fully understanding how TEAD is palmitoylated in mammalian
systems will be essential for understanding the regulation and
dynamics of this essential signaling pathway. With proteomic ef-
forts and technological advances rapidly uncovering the com-
plete human palmitoylated proteome (Chamberlain and Ship-
ston, 2015; Hannoush, 2015), it is becoming increasingly
evident that being able to modulate the lipidation state of many
proteins will be fundamental to understanding their function
and regulation in a vast assortment of cellular processes. Impor-
tantly, these efforts will, in many cases, have direct relevance to
the development and success of new therapeutic strategies.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
TEAD2-YBD (A217-D447) and TEAD3-YBD (Q216-D435) constructs contain-
ing tobacco etch virus protease-cleavable N-terminal His tags were expressed
in E. coli BL21 (DE3) cells by autoinduction and purified by standard purifica-
tion techniques for His-tagged proteins (see Supplemental Experimental Pro-
cedures for details).184 Structure 24, 179–186, January 5, 2016 ª2016 Elsevier Ltd All rights reservedCrystallization
TEAD2-YBD crystals of the body-centered mono-
clinic space group I121 were grown at 19C by
hanging-drop vapor diffusion using a drop ratioof 2:1 protein/reservoir solution. Reservoir solution contained 100 mM Tris
(pH 7.3) and 1.7–2.1 M sodium formate. Crystals were cryoprotected in reser-
voir solution supplemented with 25% glycerol.
TEAD3-YBD crystals of the primitive orthorhombic space group P212121
were also grown at 19C by hanging-drop vapor diffusion using a drop ratio
of 2:1 protein/reservoir solution. Reservoir solution contained 100 mM sodium
acetate (pH 4.5), 100 mM calcium acetate, and 12% polyethylene glycol 4000.
Crystals were cryoprotected in reservoir solution supplemented with 30%
glycerol.
Data Collection and Structure Determination
X-Ray diffraction data were collected for TEAD2-YBD and TEAD3-YBD crys-
tals at beamlines 21-ID-F at the Advanced Photon Source and 5.0.2 at the
Advanced Light Source, respectively. Data were processed using iMosflm
(Battye et al., 2011). The TEAD2-YBD structure was solved by molecular
replacement using Phaser (McCoy et al., 2007), with the previously published
TEAD2-YBD structure (Tian et al., 2010) as a search model and two mole-
cules in the asymmetric unit. The structure was then rebuilt in Coot (Emsley
and Cowtan, 2004), and subjected to iterative rounds of refinement and
rebuilding using Phenix (Adams et al., 2010) and Coot. Data processing
and refinement statistics are summarized in Table 1. Clear extra density
at C380 was modeled as an S-palmitoyl cysteine for each molecule in the
asymmetric unit.
The structure of TEAD3-YBD was also solved by molecular replacement us-
ing Phaser, with an unpalmitoylated version of our TEAD2-YBD structure as
the search model and four molecules in the asymmetric unit. The structure
was then rebuilt manually in Coot using the TEAD3-YBD sequence as a guide,
and subjected to iterative rounds of refinement and rebuilding using Phenix
and Coot. Data processing and refinement statistics are summarized in Table
1. Clear extra density at C371wasmodeled as an S-palmitoyl cysteine for each
molecule in the asymmetric unit.
Metabolic Lipid Labeling, ClickChemistry, andVisualization of TEAD
Alkyne fatty acid labeling was performed as described previously (Gao and
Hannoush, 2014; Hannoush, 2012; Hannoush and Arenas-Ramirez, 2009). A
detailed description of this and our western blotting analysis protocols are
described in Supplemental Experimental Procedures.
Immunofluorescence Imaging
HeLa, PaTu-8902, OUMS-23, or SW-1990 cells were plated on poly-lysine-
coated eight-well chamber cells at 20,000 cells/well. Following 24 hr of growth,
cells were fixedwith 4%paraformaldehyde in PBS at pH 7.4. Following perme-
abilization (0.1% Triton X-100 in PBS), blocking (2% BSA in PBS), and primary
antibody incubation (1:100 dilution), antibodies were visualized using Alexa
dye-conjugated secondary antibodies (1:1,000 dilution). Images were
collected on a Nikon A1R confocal microscope with a 100 3 1.45 Plan Apo
oil-immersion objective. Alexa 488 and Alexa 647 were imaged with the 488
and 640 laser lines, respectively. The differential interference contrast (DIC)
image was collected simultaneously with the 488 laser. DIC images presented
in Figures 4 and S4 were processed with shading correction (background
flexibility, 30; signal, average) and unsharp mask (power, 0.5; area, 5), using
NIS-Elements Imaging Software (Nikon) to correct for light variation across im-
ages and enhanced contrast to better visualize cell outlines.
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